We look forward to exploring this further.”ĬOVID brain fog refers to cognitive impairment experienced by patients who have recovered or are recovering from COVID-19. In light of the growing reports of patients experiencing cognitive impairment associated with COVID-19, and based on the data demonstrating dextroamphetamine’s ability to improve cognitive measures in patients with ADHD, we believe ADAIR has the potential to address/improve a number of these troubling symptoms/cognitive measures. This symptom, sometimes referred to as COVID brain fog, can have a significant impact on COVID-19 patients’ and survivors’ daily functioning and quality of life. New research suggests that there may be long-term neurologic consequences in many patients who survive COVID infections, including cognitive impairment and attention issues. The new US patent covers a method of use for ADAIR for treating or alleviating symptoms of cognitive impairment in patients who have had a COVID-19 infection, with a base patent term extending until 2041.ĭavid Baker, Chief Executive Officer of Vallon, said “The medical community continues to gather data and learn about COVID-19 and the ways in which it manifests in patients. 11,253,490 covering the use of its proprietary investigational abuse-deterrent formulation of dextroamphetamine, ADAIR, for the treatment of cognitive impairment (sometimes referred to as “COVID brain fog”) associated with COVID-19. recently announced the United States Patent and Trademark Office (USPTO) has issued patent No.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |